Great Valley Advisor Group Inc. Sells 4,129 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Great Valley Advisor Group Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,695 shares of the biopharmaceutical company’s stock after selling 4,129 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Gilead Sciences were worth $623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Tompkins Financial Corp lifted its position in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at $26,000. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $29,000. Rakuten Securities Inc. purchased a new position in Gilead Sciences during the 4th quarter worth $33,000. Finally, Financial Connections Group Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.8 %

Shares of GILD opened at $64.78 on Friday. The stock’s 50-day moving average price is $70.55 and its 200-day moving average price is $75.83. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $80.66 billion, a price-to-earnings ratio of 179.94, a PEG ratio of 1.30 and a beta of 0.22. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.37 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Maxim Group dropped their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group dropped their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, TD Cowen cut their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.